ClinicalTrials.gg
Active, not recruitingNCT04943536BiolenRTUpdated Feb 27, 2026

Bicalutamide Implants (Biolen) With Radiation Therapy in Patients With Localized Prostate Cancer

A Phase 1 interventional study of bicalutamide and Stereotactic body radiation therapy in Prostate Adenocarcinoma, sponsored by Alessa Therapeutics Inc.. Active, not recruiting at 1 site in United States. Open to male participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-02-27.

Sponsored by Alessa Therapeutics Inc. · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
20
Allocation
Not applicable
Ages
18 Years and older
Sex
Male
01

Study summary

This study will be undertaken to evaluate the feasibility of replacing systemic Androgen Deprivation Therapy (ADT) with targeted local delivery of an anti-androgen agent alone in patients in whom ADT + radiation therapy is indicated for the treatment of localized prostate cancer.

Read the detailed description

This study is a prospective, single-center, single-arm feasibility study. Up to 20 participants will be recruited to assess the safety and patient tolerance of Biolen for the localized delivery of bicalutamide into the prostate when delivered with radiotherapy.

At baseline, patients will undergo multiparametric MRI of the prostate. Study participants will have placement of the drug eluting Biolen implants. At the 8 week timepoint, participants will undergo repeat multiparametric MRI.

Participants will receive standard of care radiation therapy on weeks 9-11 and will be followed through 2 years post radiation. A third and fourth multiparametric MRI will be performed at 6 and 24 months after completion of radiation. Clinical labs and correlative sample collection and patient quality of life questionnaires will be administered at follow-up visits. Following completion of follow-up or removal from protocol, patients may be offered enrollment on long-term follow up protocols.

02

Conditions studied

  • Prostate Adenocarcinoma
03

In context

Lead sponsor

Alessa Therapeutics Inc. is the lead sponsor of 3 studies on the registry; 1 is open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients with proven localized prostate cancer in whom prostate radiation and ADT is appropriate therapy (such as Intermediate Risk localized prostate cancer)
  • Patients must have at least 1 MRI detected; biopsy proven prostate cancer.
  • Patients diagnosed as one of the following:

    1. National Comprehensive Cancer Network (NCCN) intermediate risk prostate cancer, OR
    2. NCCN high risk prostate cancer due to Gleason Grade 4 or 5 AND refuses to receive systemic ADT, OR
    3. NCCN high risk prostate cancer due to Prostate Specific Antigen (PSA) > 20 AND refuses to receive systemic ADT.
  • Age >18 years.

Exclusion criteria

Exclusion Criteria:

  • NCCN high risk patients eligible for treatment with systemic ADT who do not refuse systemic ADT.
  • Patients receiving prior radiotherapy or surgery for prostate cancer.
  • Patients receiving prior or ongoing ADT.
  • Study participant unwilling or unable to undergo MRI, including patients with to MRI, such as cardiac pacemakers, non-compatible intracranial vascular clips, etc.
  • Use of 5 alpha reductase inhibitors (e.g. Finasteride or Dutasteride) within 3 months of screening or total use within the last two years prior to screening of > 3 months.
  • Prostate volume more than 80 cc at prior MRI imaging.
  • International Prostate Symptom Score ≥ 20.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
20 participants (estimated)

Study arms

  • Experimental
    Biolen+Radiation Therapy

    Localized single delivery of the Biolen implant (polymer + bicalutamide) with radiation therapy

    Drug: bicalutamide · Radiation: Stereotactic body radiation therapy

Interventions

  • localized anti-androgen therapy

  • RadiationStereotactic body radiation therapy

    localized radiation therapy

06

What researchers measure

Primary outcomes

  1. Feasibility of replacing systemic androgen tx with targeted local delivery

    Ability to successfully implant the prostate with Biolen and a lack of implant toxicity that interferes with the capacity to complete intended radiation therapy.

    Time frame: 27 months

Secondary outcomes

  1. Adverse Events

    toxicity of localized delivery of bicalutamide

    Time frame: through 27 months

  2. MRI changes

    prostate and tumor volume changes

    Time frame: baseline versus 8 weeks post biolen implantation and 6 months post RT

  3. Biochemical progression free survival

    rate of biochemical progression free survival

    Time frame: 24 months post RT

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Dec 2021 (actual). Primary completion is estimated for Apr 2027, 64 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 15, 2021
First posted
Jun 29, 2021
StartActual
Dec 7, 2021
Primary completionEst.
Apr 24, 2027
CompletionEst.
Aug 15, 2027
Last update
Feb 27, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 27, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04943536
Lead sponsor
Alessa Therapeutics Inc.
Responsible party
Sponsor
First posted
Jun 29, 2021
Start date
Dec 7, 2021
Primary completion
Apr 24, 2027 (estimated)
Completion
Aug 15, 2027 (estimated)
Last update
Feb 27, 2026

Study contacts

Deborah Citrin, MD
principal investigator · National Cancer Institute (NCI)

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Feb 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Bicalutamide

Start the discussion